WFA of San Diego LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,342 shares of the company’s stock, valued at approximately $1,173,000.
Other hedge funds have also bought and sold shares of the company. Austin Private Wealth LLC lifted its stake in shares of Johnson & Johnson by 2.5% in the first quarter. Austin Private Wealth LLC now owns 2,830 shares of the company’s stock valued at $371,000 after buying an additional 68 shares during the period. Sun Life Financial INC lifted its stake in shares of Johnson & Johnson by 2.5% in the first quarter. Sun Life Financial INC now owns 2,758 shares of the company’s stock valued at $362,000 after buying an additional 68 shares in the last quarter. Winslow Evans & Crocker Inc. raised its holdings in shares of Johnson & Johnson by 0.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock valued at $3,037,000 after purchasing an additional 69 shares during the last quarter. Lathrop Investment Management Corp raised its holdings in shares of Johnson & Johnson by 1.4% in the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after purchasing an additional 69 shares during the last quarter. Finally, Reik & CO. LLC increased its holdings in Johnson & Johnson by 0.4% during the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after buying an additional 70 shares during the last quarter. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JNJ traded down $0.27 during trading hours on Wednesday, hitting $148.62. 182,433 shares of the stock were exchanged, compared to its average volume of 8,477,668. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The company has a market cap of $392.00 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68. The stock’s 50-day moving average price is $149.30 and its two-hundred day moving average price is $144.19.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.58 earnings per share. On average, research analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
A number of analysts have recently commented on JNJ shares. Citigroup boosted their target price on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a research report on Tuesday, July 7th. Finally, Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, September 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $163.00.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Compound Interest
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.